Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.51 |
| ▸ | TAS1R2 | Q8TE23 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.50 |
| ▸ | PDE2A | O00408 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 3/20 | 0.49 |
| ▸ | CNR1 | P21554 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SPR | P35270 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2736989 | 0.86 | CNR2 (0.69) | ALDH1A1PDE10ACNR2CNR1HTT | |
| SCHEMBL2736570 | 0.82 | CNR2 (0.54) | LMNACNR2CNR1 | |
| SCHEMBL13990924 | 0.76 | AHR (0.47) | CNR2CNR1 | |
| SCHEMBL2736571 | 0.76 | AHR (0.47) | CNR2CNR1 | |
| SCHEMBL26086660 | 0.76 | AHR (0.69) | MEN1KMT2ACNR2CNR1 | |
| SCHEMBL2736562 | 0.74 | CNR2 (0.52) | ALDH1A1CNR2CNR1 | |
| SCHEMBL26087097 | 0.74 | AHR (0.70) | MEN1KMT2ACNR2CNR1 | |
| SCHEMBL15953788 | 0.72 | TAS1R3 (0.65) | TAS1R3TAS1R1TAS1R2ALDH1A1MEN1 | |
| SCHEMBL15953787 | 0.72 | TAS1R3 (0.65) | TAS1R3TAS1R1TAS1R2ALDH1A1MEN1 | |
| SCHEMBL5969897 | 0.72 | TAS1R3 (0.64) | TAS1R3TAS1R1TAS1R2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088924-B2 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | TADA YUKIO | 2010-04-01 | — | — | US | disclosed |
| US-7652141-B2 | Immunosuppressants, analgesics, antiinflammatory agents | SHIONOGI & CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-20070027144-A1 | Novel use of cannabinoid receptor agonist | SHIONOGI & CO., LTD. (JP) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027144-A1 | Novel use of cannabinoid receptor agonist | CNR2, CNR1, OPRM1 | TAS1R3 381/4885TAS1R1 368/4885TAS1R2 361/4885 |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | CNR2, CNR1, NPY2R | TAS1R3 603/4885TAS1R1 848/4885TAS1R2 497/4885 |
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | TAS1R3 2500/4885TAS1R1 2345/4885TAS1R2 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.